Oklahoma House Bill HB3368

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Compound prescription drug coverage; health insurance plan providing prescription drug coverage; effective date.

Summary

HB3368 amends Oklahoma’s health insurance statute governing prescription drug coverage to expressly include compound prescription drugs in the pharmacy contracting and bidding framework. Under the bill, a health insurance plan, policy, or health maintenance organization that covers prescription drugs must allow a pharmacy or group of pharmacies to bid on pharmacy contracts at least once every three years, and that right would now extend to contracts for pharmacy services involving compound prescription drugs as well as standard prescription drugs. The bill also clarifies that insurers and HMOs may continue to operate open pharmacy networks, and it states that the bidding requirement does not apply to plans that already maintain an open pharmacy network. The measure is set to take effect November 1, 2026.

Impact

HB3368 would amend 36 O.S. 2021, Section 3634.3, expanding the statute’s scope from prescription drugs generally to include compound prescription drugs in pharmacy service contracts. Its practical effect would be to give pharmacies an explicit opportunity to compete for contracts involving compounded medications when a plan uses a closed or selective network, while preserving existing flexibility for open-network plans. The bill primarily affects health insurers, HMOs, pharmacies, and pharmacy groups participating in prescription drug benefit arrangements.

Sentiment

Based on the available record, the bill appears to have a neutral-to-supportive posture, but there is little direct evidence of debate because no committee transcripts or recorded votes are available. The bill advanced to second reading and was referred to Rules, suggesting it was moving through the legislative process without documented controversy at this stage.

Contention

The main policy issue implied by the bill is whether insurers should be required to extend pharmacy contract bidding rights to compound prescription drugs, which can be more specialized and potentially more costly than standard prescriptions. Pharmacies and pharmacy groups would likely favor the added contracting opportunity, while insurers and HMOs may be concerned about administrative burden, network management, or cost implications. The bill’s exception for open pharmacy networks also suggests a possible point of distinction between plans that use selective contracting and those that already allow broader pharmacy participation.